{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:52Z","timestamp":1789958872776,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.exphem.2015.08.004","type":"journal-article","created":{"date-parts":[[2015,8,23]],"date-time":"2015-08-23T00:01:14Z","timestamp":1440288074000},"page":"1015-1018.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"43","author":[{"given":"Giovanni","family":"Caocci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata Monika","family":"Trawinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ragatzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Barat\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Labate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Littera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Carcassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gambacorti","family":"Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"La Nasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2015.08.004_bib1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2015.08.004_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.004_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2015.08.004_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2015.08.004_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11899-013-0190-1","article-title":"Immunology and immunotherapy of chronic myeloid leukemia","volume":"9","author":"Ilander","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.exphem.2015.08.004_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1399-0039.2009.01235.x","article-title":"Killer immunoglobulin-like receptors (KIR2DL2 and\/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukemia","volume":"73","author":"Middleton","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.exphem.2015.08.004_bib7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","article-title":"KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib","volume":"26","author":"Marin","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.08.004_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","article-title":"Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia","volume":"40","author":"Kreutzman","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2015.08.004_bib9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/cas.12216","article-title":"Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib","volume":"104","author":"Mizoguchi","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2015.08.004_bib10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2013-06-508465","volume":"122","author":"Rea","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.004_bib11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.V124.21.812.812","article-title":"Early disease relapse after tyrosine kinase inhibitor treatment discontinuation in CML is related both to low number and impaired function of NK-Cells","volume":"124","author":"Ilander","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.004_bib12","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/cbt.8.23.10455","article-title":"Natural killer cells and cancer: regulation by\u00a0the killer cell Ig-like receptors (KIR)","volume":"8","author":"Purdy","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.exphem.2015.08.004_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1034\/j.1600-065X.2002.19004.x","article-title":"The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism","volume":"190","author":"Hsu","year":"2002","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2015.08.004_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","article-title":"Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients","volume":"41","author":"La Nasa","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2015.08.004_bib15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V124.21.813.813","article-title":"The risk of relapse in CML patients who discontinued imatinib can be predicted based on patients age and the results of dPCR analysis","volume":"124","author":"Mori","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.004_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri3370","article-title":"Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution","volume":"13","author":"Parham","year":"2013","journal-title":"Nat Rev Immunol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X15006116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X15006116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:09:21Z","timestamp":1654924161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X15006116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0301472X15006116"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2015.08.004","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2015.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}